LEAP Technologies Inc. (LEAP), Carrboro, NC, USA and Antec, Zoeterwoude, The Netherlands, announced their collaboration in the field of sample preparation for HDX/MS.
LEAP is a provider of automated Hydrogen Deuterium Exchange (HDX) workstations that allow for labeling, quenching and injection of protein samples under cold conditions. Antec is a provider of the ROXY electrochemical system, providing fast and efficient electrochemical reduction of disulfide bonds in proteins/peptides. The integration the ROXY EC system into LEAP’s PAL HDX workstation will assure a fully automated HDX/EC/MS workflow which can be used with every mass spectrometer.
The full integration enables reducing disulfide bonds in proteins/peptides in only a fraction of the time compared with the use of reducing agents (TCEP). Large and highly disulfide-stabilized proteins (e.g., cystine knots) previously difficult to reduce chemically are now accessible for HDX, resulting in an overall increased sequence coverage. Jean-Pierre Chervet (CEO Antec) comments: we are excited to collaborate with LEAP the world leader in HDX automation and to bring HDX/MS to a new level of customer satisfaction by integrating the disulfide bond reduction.
LEAP and Antec are proud to be providing an improved customer solution of HDX/EC/MS integration.
At ASMS, June 5-9, 2016, both companies will present this approach.
For more information feel free to visit Antec booth # 700 or LEAP Technologies booth # 623. LEAP is part of the Trajan family - you can also meet the team from Trajan Scientific and Medical at booth # 403.
Press Release [PDF]
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.